Activity of anti-cancer protein kinase inhibitors against Leishmania spp. | Zendy

Lisa Sanderson | Zendy; Vanessa Yardley | Zendy; Simon L. Croft | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Activity of anti-cancer protein kinase inhibitors against Leishmania spp.

Author(s) -

Lisa Sanderson,

Vanessa Yardley,

Simon L. Croft

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku069

Subject(s) - miltefosine , lapatinib , amastigote , sunitinib , pharmacology , leishmania mexicana , leishmania , sorafenib , in vivo , leishmania donovani , leishmania major , kinase , potency , medicine , visceral leishmaniasis , biology , leishmaniasis , cancer , in vitro , immunology , cancer research , biochemistry , hepatocellular carcinoma , parasite hosting , microbiology and biotechnology , trastuzumab , breast cancer , world wide web , computer science

There is an urgent need to develop new and effective treatments for poverty-related neglected diseases. In light of the time required to bring a new drug to market and the cost involved (10-15 years, >1 billion US$), one approach to identifying new treatments for diseases like leishmaniasis is to evaluate drugs that are already registered for the treatment of other diseases. This paper describes the anti-leishmanial activities of 10 FDA-approved protein kinase inhibitors already available for the treatment of human cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research